TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
- Inclusion in the Cancer Drugs Fund will give more women in England and Wales with recurrent, platinum-sensitive ovarian cancer access to ZEJULA via a managed access arrangement
- ZEJULA was launched in the private market in the UK at the end of 2017
ZUG, Switzerland, June 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the National Institute for Health and Care Excellence (NICE) will make ZEJULA® (niraparib), the first PARP inhibitor shown to be effective in patients with a BRCA mutation as well as those without a BRCA mutation, available to women in England and Wales with recurrent platinum-sensitive ovarian cancer via the Cancer Drugs Fund (CDF)1. NICE has recommended ZEJULA via the CDF for women with a BRCA mutation who have received two lines of chemotherapy and in women without a BRCAmutation who have received two or more lines of chemotherapy.
"At TESARO, we continue to globalize our mission and bring transformative therapies to patients. We are pleased that NICE will now provide more women with recurrent ovarian cancer in England and Wales access to ZEJULA through the CDF," said Orlando Oliveira, Senior Vice President and General Manager, TESARO International. "Through close partnership with both NICE and NHS, TESARO can now offer ZEJULA as an option for second-line maintenance treatment, regardless of a patient's BRCA status."
The CDF is a source of funding for cancer drugs in England, providing patients access to promising new oncology treatments while NHS England and NICE analyze any additionally requested data to inform a final reimbursement decision on a new treatment or indication. Overall survival data for ZEJULA are not yet available, and as a result NICE has recommended ZEJULA for use within the CDF while further data are collected2. Interim funding is provided via the CDF, giving patients access to the treatment through a managed access arrangement.
"Recurrent ovarian cancer is an aggressive form of cancer where a key goal of treatment is to keep women in remission and off chemotherapy for as long as possible - allowing them the best chance for a good quality of life," said Jonathan Ledermann, Professor of Medical Oncology at the University College London Cancer Institute. "ZEJULA offers the chance to delay this cancer from returning or progressing for months, and possibly years in some cases. It is a significant step forward. Crucially, this decision opens the door for many women who, until now, have not had the option of maintenance treatment with a PARP inhibitor."
About Ovarian Cancer
In the UK, ovarian cancer has the highest mortality rate of all gynecological cancers3. It has one of the highest incidence rates in Europe4 with survival rates among the lowest5. The rate of newly diagnosed cases of ovarian cancer in the UK is 16 per 100,000 of the population compared to the European average of 12.6 per 100,0005. Every year 4,100 women lose their lives to ovarian cancer - 11 women every day6.
The most common symptoms of ovarian cancer include abdominal or pelvic pain, bloating, difficulty eating, and urinary urgency, all of which are commonly associated with less serious conditions. 60% of women with ovarian cancer are diagnosed in an advanced stage7, when prognosis is poor. Although significant progress has been made in treatment of ovarian cancer, the disease recurs in approximately 85% of women with advanced ovarian cancer8, at which point it may be incurable9 ,10. Recurrent ovarian cancer is the sixth most common cause of cancer death among women and has the highest mortality rate of all gynecological cancers.
Niraparib is marketed in the United States and Europe under trade name ZEJULA®. ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. In preclinical studies, ZEJULA concentrates in the tumor relative to plasma, delivering greater than 90% durable inhibition of PARP 1/2 and a persistent antitumor effect.
ZEJULA is approved in Europe as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response (CR) or partial response (PR) to platinum-based chemotherapy. The approval was based on data from the clinically rigorous ENGOT-OV16/NOVA trial, a double-blind, placebo-controlled, international Phase 3 study of ZEJULA that enrolled 553 patients with recurrent ovarian cancer who had achieved either a PR or CR to their most recent platinum-based chemotherapy. ZEJULA is the first once-daily, oral poly (ADP-ribose) polymerase (PARP)1/2 inhibitor to be approved in Europe that does not require BRCA mutation or other biomarker testing.
The primary endpoint of the trial was progression free survival (PFS). Approximately two-thirds of study participants did not have germline BRCA mutations. Progression in the NOVA study was determined by a robust, unbiased, blinded central review to be the earlier of radiographic or clinical progression. ZEJULA significantly increased PFS in patients with or without germline BRCA mutations as compared to the control arm. Treatment with ZEJULA reduced the risk of disease progression or death by 73% in patients with germline BRCA mutations (hazard ration (HR) 0.27) and by 55% in patients without germline BRCA mutations (HR 0.45). The magnitude of benefit was similar for patients entering the trial with a PR or a CR.
The approved starting dose of ZEJULA is 300 milligrams once per day. According to the European summary of product characteristics (SmPC), in patients below 58 kilograms, a starting dose of 200 milligrams once per day may be considered. The most commonly administered dose of ZEJULA over the course of the Phase 3 NOVA clinical trial was 200 milligrams once per day, following dose modification. Further exploratory analyses of the NOVA study indicated that individual dose modification maintained efficacy and reduced the rate of new adverse events.11
ZEJULA (niraparib) Select Important Safety Information
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) was reported in patients treated with ZEJULA in some clinical studies. Discontinue ZEJULA if MDS/AML is confirmed. Hematologic adverse reactions (thrombocytopenia, anemia and neutropenia) have been reported in patients treated with ZEJULA. Do not start ZEJULA until patients have recovered from hematological toxicity caused by previous chemotherapy (less that or equal to Grade 1). Monitor complete blood counts weekly for the first month, monthly for the next 11 months of treatment, and periodically after this time.
Hypertension and hypertensive crisis have been reported in patients treated with ZEJULA. Monitor blood pressure and heart rate monthly for the first year and periodically thereafter during treatment with ZEJULA. Closely monitor patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
Based on its mechanism of action, ZEJULA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for six months after receiving the final dose. Because of the potential for serious adverse reactions in breastfed infants from ZEJULA, advise a lactating woman not to breastfeed during treatment with ZEJULA and for one month after receiving the final dose.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
TESARO Global Investor and Media Contact
Vice President, Corporate Affairs & Investor Relations
TESARO Media Contact Outside the U.S.:
Head of Corporate Affairs, International
+41 (0) 41 588 08 68
1 National Institute for Health and Care Excellence Final appraisal determination. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
2 Cancer Research UK, Ovarian cancer statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Accessed May 2018.
3 Cancer Research UK, Ovarian cancer statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Accessed May 2018.
4 World Cancer Research Fund Initiative. Ovarian cancer statistics, Available at: https://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/ovarian-cancer-statistics. Accessed May 2018.
5 OCAM, Facts and figures. Available at http://ocam.org.uk/ovarian-cancer-facts-and-figures/. Accessed May 2018.
6 Cancer Research UK, Ovarian cancer statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Accessed May 2018.
7 ENGAGe. ESGO. Ovarian cancer factsheet. what is ovarian cancer? Available at: https://engage.esgo.org/media/2017/08/ENGAGe_What_is_ovarian_cancer_en_V01.pdf. Accessed April 2018.
8 Lorusso D, Mancini M, Di Rocco R, Fontanelli R, & Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol 2012; doi: 10.1155/2012/613980.
9 Chien J, Kuang R, Landen C, et al. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. frontiers in oncology. 2013;3:article 251.
10 Birrer M, Fujiwara K. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: platinum-resistant disease. 2016. Available at: https://www.uptodate.com/contents/medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-resistant-disease. Accessed April 2018.
11 Wang J et al. The Exposure-Response Relationship of Niraparib in Patients with gBRCAmut and Non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial. ESMO; 2017 Sep 8-12; Madrid, Spain.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TESARO, Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 201916.7.2019 22:00:00 CEST | Press release
LYON, France and CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: Appointment of Jean-Paul KRESS as director; he was subsequently appointed to the position of Chairman of the Board of Directors; Renewal of the term of office of each of the following as a member of the Board of Directors: o Gil BEYEN; o Luc DOCHEZ; o Philippe ARCHINARD; o Galenos, represented by Sven ANDREASSON; Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2018 and quietus of directors; Allocation of the financial year's results; Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; Approval of the regulations of the share subscription and/or purchase
LGC Capital Ltd. Announces Change in Financial Year-End16.7.2019 18:30:00 CEST | Press release
MONTRÉAL, July 16, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) wishes to announce that it is changing its financial year-end to December 31 from its current year-end of September 30. As a result, LGC will file an additional interim report as at September 30, 2019 and will report audited financial results for a 15-month transition year from October 1, 2018 to December 31, 2019 (with a comparative of the 12 months ended September 30, 2018). Afterwards, LGC will revert to a customary reporting calendar based on a December 31 year-end, with fiscal quarters ending on the last day of March, June, September and December each year. LGC believes this change of financial year-end will allow it to complete the audit requirements of its investee companies with greater efficiency and will be useful to consolidate other companies in the future. The notice for the change in financial year-end required under Regulation 51-102 respecting Continuous Disclosure Obligations will b
UPDATE -- OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:53:00 CEST | Press release
First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers Monetize Customer Relationships SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to addres
OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:00:00 CEST | Press release
First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to address the complex customer identific
Agreement with Eurekahedge Expands eVestment’s Hedge Fund Data Offering16.7.2019 14:00:00 CEST | Press release
ATLANTA, July 16, 2019 (GLOBE NEWSWIRE) -- eVestment, a global leader in institutional investment data and analytics, today announced an agreement with Eurekahedge to offer Eurekahedge fund data and indices to clients of eVestment’s suite of Analytics solutions. eVestment Analytics clients will now have access to Eurekahedge’s global hedge fund data and indices, which cover over 30,000 hedge funds and funds of hedge funds spanning North American, European, Asian, Latin American and emerging markets. This expansion of data capabilities on the eVestment platform furthers eVestment’s focus on providing the most comprehensive institutional investment data to clients around the world across a wide variety of asset classes, including traditional investment strategies, hedge funds, funds of hedge funds and private markets investment opportunities. “Our clients need the most comprehensive data available to make the best decisions,” said eVestment Global Head of Insights John Molesphini. “Addin
ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CEST | Press release
Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be